Earnings: Zydus Lifesciences reported a 30% YoY rise in Q3FY25 net profit to ₹1,023.5 crore, driven by strong US growth.

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which ...

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also ...

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of ...

KR Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1201 in its ...

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 1050 in its research report ...

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

Zydus Lifesciences Ltd (BOM:532321) reports a robust 17% revenue increase and significant advancements in its innovation pipeline amidst market challenges.

The company's Consumer Wellness business registered revenues of Rs. 448.8 crore, up 13 % y-o-y with 4.8% volume growth.

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...